Stanford University
Showing 5,081-5,100 of 34,836 Results
-
Edward C. Cheng
Affiliate, FSI
BioDr. Edward C. Cheng is a technology strategist and visionary leader. He serves as Senior Advisor for the cross-industry Safe AI Agents Consortium Group, whose members include Anthropic, Cohere, Meta, Microsoft, Oracle, PayPal, DoorDash, PwC, Inquiryon, and others. He is also the Chief Technology Officer and Executive Chairman of Inquiryon. Previously, Edward served as VP of AI at Oracle NetSuite and held senior leadership roles at HP.
Edward is the lead inventor of the Log-Structured Merge Tree (LSM Tree), a foundational data structure that enables low-latency, high-throughput, and high-velocity data processing. It is widely adopted by major data management systems across industry, including Google, Meta, X, Microsoft, Oracle, Hadoop, Cassandra, MongoDB, RocksDB, and many others.
His work on Safe AI Agents focuses on governance frameworks, human-centric AI principles, and multi-agent systems that align autonomous AI with democratic values and human oversight. He collaborates across academia, industry, and civil society to advance research, publish scholarly work, and help shape emerging best practices for safe and trustworthy AI agent development and deployment. He also speaks globally about the impacts and risks of AI agents and AGI with diverse communities.
Edward writes under the pen name Edward Sizhe on topics spanning faith, technology, and life purpose. His books include "AI and God," "Journey of Life or Death," and "Five Questions Toward Enriching the Meaning and Purpose of Life, available on Kindle and Amazon."
His research interests include AI agents, distributed big data systems, machine learning and deep learning, parallel search algorithms, high-performance computing, and distributed systems. He is also interested in biblical studies and archaeological evidence surrounding biblical events. Edward has published numerous scientific papers and holds multiple patents in AI, machine learning, and database systems. He previously worked with the Stanford Database Research Group and now serves as Senior Advisor and researcher at the Stanford Deliberative Democracy Lab.
Edward received his PhD in Computer Science from the University of London, his master’s degree from UC Berkeley, and an MBA from Columbia University. -
Evaline Cheng, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardio-oncology
Cardiotoxicity
Delivery of care
Health care systems -
Hannah Cheng
Soc Science Rsch Prof 3, Psych/Public Mental Health & Population Sciences
BioHannah Cheng, MS is a Research Scientist at the Stanford Center for Dissemination and Implementation. Her overarching goal is to leverage implementation science to dismantle systemic barriers and improve access to behavioral health services. Her work focuses on identifying strategies to implement innovations in resource-limited settings and integrating economic evaluations in implementation research to maximize return on investment
-
Jordan C. Cheng, DMD, PhD
Postdoctoral Scholar, Stanford Cancer Institute
Current Research and Scholarly InterestsMy research direction involves the evalutation of single-stranded library prepartion methods versus conventional double-stranded methods of cell-free DNA for non-invasive cancer profiling applications. The exploration of these technologies allow for the inference of the genomic and epigenetic features of both local and distant cell types associated with a biofluid.
-
Paul Cheng MD PhD
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford, including a post-doctoral training in the Quertermous lab. His current clinical focus is in amyloidosis and cardio-oncology.
Dr. Cheng pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome. The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.
Find out more about what the Cheng lab is up to, check out https://chenglab.stanford.edu
